Blood, 1 March 2004, Vol. 103, No. 5, pp. 1799-1806.
Prepublished online as a Blood First Edition Paper on September 11, 2003; DOI 10.1182/blood-2003-02-0402.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
Identification of genes modulated in multiple myeloma using genetically identical twin samples
Nikhil C. Munshi,
Teru Hideshima,
Daniel Carrasco,
Masood Shammas,
Daniel Auclair,
Faith Davies,
Nicholas Mitsiades,
Constantine Mitsiades,
Ryung Suk Kim,
Cheng Li,
S. Vincent Rajkumar,
Rafael Fonseca,
Lief Bergsagel,
Dharminder Chauhan, and
Kenneth C. Anderson
From the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute and the Boston VA Healthcare System, Harvard Medical School, the Harvard School of Public Health, Boston, MA; the University of Leeds, United Kingdom; the Mayo Clinic Medical Center, Rochester, MN; and the Weil College of Cornell University, New York, NY.
Genetic heterogeneity between individuals confounds the comparison of gene profiling of multiple myeloma (MM) cells versus normal plasma cells (PCs). To overcome this barrier, we compared the gene expression profile of CD138+ MM cells from a patient bone marrow (BM) sample with CD138+ PCs from a genetically identical twin BM sample using microarray profiling. Two hundred and ninety-six genes were up-regulated and 103 genes were down-regulated at least 2-fold in MM cells versus normal twin PCs. Highly expressed genes in MM cells included cell survival pathway genes such as mcl-1, dad-1, caspase 8, and FADD-like apoptosis regulator (FLIP); oncogenes/transcriptional factors such as Jun-D, Xbp-1, calmodulin, Calnexin, and FGFR-3; stress response and ubiquitin/proteasome pathway–related genes and various ribosomal genes reflecting increased metabolic and translational activity. Genes that were down-regulated in MM cells versus healthy twin PCs included RAD51, killer cell immunoglobulin-like receptor protein, and apoptotic protease activating factor. Microarray results were further confirmed by Western blot analyses, immunohistochemistry, fluorescent in situ hybridization (FISH), and functional assays of telomerase activity and bone marrow angiogenesis. This molecular profiling provides potential insights into mechanisms of malignant transformation in MM. For example, FGFR3, xbp-1, and both mcl-1 and dad-1 may mediate transformation, differentiation, and survival, respectively, and may have clinical implications. By identifying genes uniquely altered in MM cells compared with normal PCs in an identical genotypic background, the current study provides the framework to identify novel therapeutic targets.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
A. Suvannasankha, C. D. Crean, R. Shanmugam, S. S. Farag, R. Abonour, H. S. Boswell, and H. Nakshatri
Antimyeloma Effects of a Sesquiterpene Lactone Parthenolide
Clin. Cancer Res.,
March 15, 2008;
14(6):
1814 - 1822.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Mahtouk, D. Hose, J. De Vos, J. Moreaux, M. Jourdan, J. F. Rossi, T. Reme, H. Goldschmidt, and B. Klein
Input of DNA Microarrays to Identify Novel Mechanisms in Multiple Myeloma Biology and Therapeutic Applications
Clin. Cancer Res.,
December 15, 2007;
13(24):
7289 - 7295.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. B. Axelsen, J. Lotem, L. Sachs, and E. Domany
Genes overexpressed in different human solid cancers exhibit different tissue-specific expression profiles
PNAS,
August 7, 2007;
104(32):
13122 - 13127.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Kiziltepe, T. Hideshima, K. Ishitsuka, E. M. Ocio, N. Raje, L. Catley, C.-Q. Li, L. J. Trudel, H. Yasui, S. Vallet, et al.
JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells
Blood,
July 15, 2007;
110(2):
709 - 718.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Mulligan, C. Mitsiades, B. Bryant, F. Zhan, W. J. Chng, S. Roels, E. Koenig, A. Fergus, Y. Huang, P. Richardson, et al.
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib
Blood,
April 15, 2007;
109(8):
3177 - 3188.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Shammas, P. Neri, H. Koley, R. B. Batchu, R. C. Bertheau, V. Munshi, R. Prabhala, M. Fulciniti, Y. t. Tai, S. P. Treon, et al.
Specific killing of multiple myeloma cells by (-)-epigallocatechin-3-gallate extracted from green tea: biologic activity and therapeutic implications
Blood,
October 15, 2006;
108(8):
2804 - 2810.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Hideshima, D. Chauhan, P. Richardson, and K. C. Anderson
Identification and Validation of Novel Therapeutic Targets for Multiple Myeloma
J. Clin. Oncol.,
September 10, 2005;
23(26):
6345 - 6350.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Raje, S. Kumar, T. Hideshima, A. Roccaro, K. Ishitsuka, H. Yasui, N. Shiraishi, D. Chauhan, N. C. Munshi, S. R. Green, et al.
Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma
Blood,
August 1, 2005;
106(3):
1042 - 1047.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Lotz, S. A. Mutallib, N. Oehlrich, U. Liewer, E. A. Ferreira, M. Moos, M. Hundemer, S. Schneider, S. Strand, C. Huber, et al.
Targeting Positive Regulatory Domain I-Binding Factor 1 and X Box-Binding Protein 1 Transcription Factors by Multiple Myeloma-Reactive CTL
J. Immunol.,
July 15, 2005;
175(2):
1301 - 1309.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. E. MacCallum, J. Melville, S. Frame, K. Watt, S. Anderson, A. Gianella-Borradori, D. P. Lane, and S. R. Green
Seliciclib (CYC202, R-Roscovitine) Induces Cell Death in Multiple Myeloma Cells by Inhibition of RNA Polymerase II-Dependent Transcription and Down-regulation of Mcl-1
Cancer Res.,
June 15, 2005;
65(12):
5399 - 5407.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Zhu, G. Somlo, B. Zhou, J. Shao, V. Bedell, M. L. Slovak, X. Liu, J. Luo, and Y. Yen
Fibroblast growth factor receptor 3 inhibition by short hairpin RNAs leads to apoptosis in multiple myeloma
Mol. Cancer Ther.,
May 1, 2005;
4(5):
787 - 798.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. S. Abraham, K. V. Ballman, A. Dispenzieri, D. E. Grill, M. K. Manske, T. L. Price-Troska, N. G. Paz, M. A. Gertz, and R. Fonseca
Functional gene expression analysis of clonal plasma cells identifies a unique molecular profile for light chain amyloidosis
Blood,
January 15, 2005;
105(2):
794 - 803.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Hideshima, P. L. Bergsagel, W. M. Kuehl, and K. C. Anderson
Advances in biology of multiple myeloma: clinical applications
Blood,
August 1, 2004;
104(3):
607 - 618.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
